OUTRACE Studies 
Resource Library

This website provides information and resources on the OUTRACE studies, which are evaluating the T cell engager, CLN-978. CLN-978 is an investigational therapeutic approach that has the potential to offer a convenient, off-the-shelf, subcutaneously delivered therapeutic option for people living with autoimmune diseases.

OUTRACE Studies

CLN-978 is being evaluated for use in the following conditions. Patients can navigate to clinicaltrials.gov or euclinicaltrials.eu by clicking the links below. Clinical trial sites may access their respective study portals by clicking on the blue access button(s) in each study card and entering in their username and password details.

Click below to learn more about the OUTRACE RA study:

clinicaltrials.gov euclinicaltrials.eu

Rheumatoid Arthritis (RA)

CLN-978 is currently being studied in a Phase 1 clinical trial in patients with treatment-refractory RA.

Access RA Materials

Click below to learn more about the OUTRACE Sjögren's study:

clinicaltrials.gov euclinicaltrials.eu

Sjögren's Disease 

CLN-978 is currently being studied in a global Phase 1b clinical trial in patients with moderate to severe Sjögren's Disease.

Access Sjögren's Materials

Click below to learn more about the OUTRACE SLE study:

clinicaltrials.gov

Systemic Lupus Erythematosus (SLE) 

CLN-978 is currently being studied in a global Phase 1b clinical trial in patients with moderate to severe SLE.

Access SLE Materials

INTRODUCTION TO TCEs AND CLN-978